Market closed
Geron/$GERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Geron
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Ticker
$GERN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
229
ISIN
US3741631036
Website
Geron Metrics
BasicAdvanced
$764M
-
-$0.21
0.76
-
Price and volume
Market cap
$764M
Beta
0.76
52-week high
$5.34
52-week low
$1.17
Average daily volume
13M
Financial strength
Current ratio
7.865
Quick ratio
6.835
Long term debt to equity
86.184
Total debt to equity
86.184
Interest coverage (TTM)
-5.77%
Management effectiveness
Return on assets (TTM)
-16.07%
Return on equity (TTM)
-45.35%
Valuation
Price to revenue (TTM)
6.827
Price to book
2.85
Price to tangible book (TTM)
2.85
Price to free cash flow (TTM)
-3.884
Growth
Revenue change (TTM)
22,264.04%
Earnings per share change (TTM)
-38.93%
3-year revenue growth (CAGR)
338.53%
3-year earnings per share growth (CAGR)
-16.36%
What the Analysts think about Geron
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Geron Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Geron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Geron News
AllArticlesVideos
Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN
Accesswire·3 days ago
Geron Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. May 12 2025 Deadline to file Lead Plaintiff Motion.
GlobeNewsWire·3 days ago
Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Geron stock?
Geron (GERN) has a market cap of $764M as of May 15, 2025.
What is the P/E ratio for Geron stock?
The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of May 15, 2025.
Does Geron stock pay dividends?
No, Geron (GERN) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Geron dividend payment date?
Geron (GERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Geron?
Geron (GERN) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.